A Study YL201 in Patients With Selected Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2027-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors. The study will include 2 parts: Phase 1 dose expansion stage (Part 1) followed by a Phase 2 stage with expanded sample size (Part 2).

Part 1 will estimate the RP2D in dose expansion cohorts of patients with not linited to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), esophageal squamous cell carcinoma (ESCC), metastatic castration-resistant prostate cancer (mCRPC), etc..

Part 2 will include patients with selected advanced solid tumor types enrolled at the RP2D to further assess the efficacy and safety of YL201.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Criteria

Inclusion Criteria:

• Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF.

• Age ≥18 years old and ≤75 years old

• Histologically or cytologically confirmed at diagnosis of NSCLC/SCLC/NPC/ESCC /mCRPC

• At least one extracranial measurable lesion according to RECIST 1.1.

• Archived or fresh tumor tissue samples can be provided.

• Eastern Cooperative Oncology Group - performance scale (ECOG PS) score of 0 or 1.

• Female subjects with fertility must agree to take high-efficiency contraceptive measures from screening to whole study period and within at least 6 months after last administration of investigational drug. Male subjects must agree to take high-efficiency contraceptive measures from screening to whole study period and within at least 6 months after last administration of investigational drug.

• Life expectancy ≥3 months.

• Capable or willing to observe the visits and procedures stipulated in study protocol.

Exclusion Criteria:

• Prior treatment with products targeting B7H3 (including antibodies, antibody-drug conjugate [ADC], chimeric antigen receptor T cells [CAR-T], and other drugs).

• Prior treatment with topoisomerase 1 inhibitors or ADC based on topoisomerase 1 inhibitors.

• Participation in another clinical trial meanwhile, except observatory (non-interventional) clinical trial or at follow-up period of interventional study.

• Washout period of previous anticancer treatment was insufficient before first administration of investigational drug.

• Major surgery (excluding diagnostic surgery) within 4 weeks before first administration of investigational drug or likely to require major surgery during the study.

• History of allogenic bone marrow transplantation or solid organ transplantation.

• Treatment with systemic steroid (Prednisone >10 mg/d or equivalent drugs) or other immunosuppressive drugs within 2 weeks before first administration of investigational drug.

• Live vaccination within 4 weeks before first administration of investigational drug or likely to require live vaccine inoculation during the study.

• Evidence of leptomeningeal metastasis or carcinomatous meningitis.

• Evidence of brain metastasis or spinal cord compression.

• Evidence of cardiovascular disease with uncontrolled state or clinical significance.

• Clinically significant concomitant lung disease.

• Diagnosed as Gilbert syndrome.

• Complicated with uncontrolled third-space effusion .

• History of gastrointestinal perforation and/or fistula within 6 months before first administration.

• History of serious infection (Grade ≥3 of NCI CTCAE) before first administration.

• Known as infection with human immunodeficiency virus (HIV).

• Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).

• History of any other primary malignant tumor within 5 years before first administration of investigational drug.

• The toxicity of previous anticancer treatment is not resolved.

• History of serious hypersensitive reactions to drug substance, inactive compositions of preparations or other monoclonal antibodies.

• Breastfeeding women. Or women confirmed as pregnant through pregnancy test within 3 days before first administration.

• Any disease, medical state, organ/system dysfunction or social state considered by investigators as possibly interfering the subject's capability for ICF signing, producing adverse influence on the subject's capability for cooperation and study participation or influencing the interpretation of study results. Including but not limited to mental disease or substance/alcohol abuse.